NEW ORLEANS, March 26, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the company's novel engineered heparin, M118, demonstrated superior efficacy to a standard dose of unfractionated heparin (UFH) in an animal model of acute arterial thrombosis. The electrolytic injury model mimics the physiological response that occurs following the rupture of an atherosclerotic plaque in a coronary artery, and indicates the potential for M118 to be used in patients diagnosed with acute coronary syndromes (ACS). The data was presented today at the American College of Cardiology's (ACC) 56th Annual Scientific Session.